Can primaquine therapy for vivax malaria be improved?
Can primaquine therapy for vivax malaria be improved?
复制标题
DOI：
10.1016/s1471-4922(03)00005-9
复制
发表时间：
2003-03-01
影响因子：
9.6
通讯作者：
Rieckmann, KH
中科院分区：
文献类型：
--
作者：
Baird, JK;Rieckmann, KH
间日疟原虫引起的地方性疟疾的发病率和范围在过去30年中有所扩大。这种寄生虫在肝脏中形成催眠虫，形成一个持续的感染库。50年前推出的伯氨喹（PQ）是唯一可用来消除催眠虫的药物。然而，较长的疗程和随访期不利于评估该药预防复发的有效性。对标准疗法的耐药性可能很普遍。迫切需要研究来衡量这一问题，并确定较短疗程和较高剂量PQ的安全性、耐受性和有效性。
The incidence and range of endemic malaria caused by Plasmodium vivax has expanded during the past 30 years. This parasite forms hypnozoites in the liver, creating a persistent reservoir of infection. Primaquine (PQ), introduced 50 years ago, is the only drug available to eliminate hypnozoites. However, lengthy treatment courses and follow-up periods are not conducive to assessing the effectiveness of this drug in preventing relapses. Resistance to standard therapy could be widespread. Studies are urgently needed to gauge this problem and to determine the safety, tolerability and efficacy of shorter courses and higher doses of PQ.